An implicit price of a DALY for use in a cost-benefit analysis of ARVs
This article uses the revealed preference approach to estimate the price for a Disability Adjusted Life Year (DALY) implied by grant decisions by the Global Fund for AIDS, tuberculosis (TB) and malaria (GFATM). A cost-benefit criterion is used that requires the DALY price exceed the cost-effectiveness ratio. The estimated price was $6300 for a DALY saved from any disease, but it was $11 900 from a DALY saved specifically from HIV/AIDS. Estimates of the cost-effectiveness ratios of Antiretroviral Drug Therapies (ARVs) in the literature were examined. At the DALY prices implicit by GFATM decisions, ARVs would be socially worthwhile.
Volume (Year): 43 (2011)
Issue (Month): 11 ()
|Contact details of provider:|| Web page: http://www.tandfonline.com/RAEC20 |
|Order Information:||Web: http://www.tandfonline.com/pricing/journal/RAEC20|
When requesting a correction, please mention this item's handle: RePEc:taf:applec:v:43:y:2011:i:11:p:1413-1421. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Michael McNulty)
If references are entirely missing, you can add them using this form.